Total
0
Shares
G Medical Innovations (ASX:GMV) - CEO, Dr Yacov Geva
CEO, Dr Yacov Geva
Sourced: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Homestay Care (HSC) and G Medical Innovations (GMV) have signed an agreement to integrate and distribute GMV’s Prizma system into the uVue platform
  • Homestay’s uVue platform monitors the health of the elderly, while G Medical’s Prizma device is a monitoring system that detects vital signs
  • Together, these technologies will be provided in aged care facilities
  • As the elderly generally don’t use smart devices, this combined system will connect to their TV at home so they can comfortably check their signs and read messages
  • If any issues are detected, they will be stored in the cloud, allowing a doctor to act straight away
  • Homestay Care is trading flat in mid-morning trade at 0.6 cents per share. G Medical is also in the grey and shares are trading for 11 cents each

Homestay Care (HSC) and G Medical Innovations (GMV) have signed an agreement to integrate and distribute GMV’s Prizma vital signs portal into the HSC IoT Platform.

The integration of these systems will provide remote vital signs monitoring capabilities to the uVue Telehealth platform and 24-hour monitoring response centre.

G Medical’s Prizma device is a remote vital signs monitoring system that is a clinical grade product and certified Therapeutic Goods Administration (TGA) approved in Australia.

Prizma includes a mobile medical device, a smart device app, and a web portal. After each test, the measurements are automatically sent to the portal for review by a monitoring centre clinician and shared with a health professional.

This integration will mould into an effective communication method for the elderly who generally don’t use smart devices or phones.

A TV, however, is the technology medium that this demographic feels comfortable using and interacts with on a daily basis.

Thus, the uVue platform connects to a client’s TV — a simple operating system with a single remote control.

The Prizma platform will be integrated on the uVue TV application, so the resident is prompted daily to take their vital signs via on-screen messaging. These results are then stored and if any issues are detected by analytics then the resident will be followed up by proactive response service.

“Usability being forefront in the aged care space, we feel that the Prizma platform exceeded our requirements, and we are looking forward to working with the G Medical team on the offering,” Homestay Care Managing Director Graham Russell said.

“This agreement with HomeStay is another example of the Prizma’s adaptability and potential to improve quality of life in everyday consumers,” G Medical CEO Dr Yacov Geva said.

“HomeStay’s uVue platform is a unique offering and provides a significant opportunity for the company and its planned expansion into Australia and New Zealand,” Yacov added.

The agreement is for an initial term of 12 months and will automatically be renewed unless either party objects.

Homestay Care is trading flat in mid-morning trade at 0.6 cents per share. G Medical is also in the grey and shares are trading for 11 cents each.

HSC by the numbers
More From The Market Herald
Amplia Therapeutics - CEO and MD, John Lambert

" Amplia Therapeutics (ASX:ATX) granted $2.1 million R&D cash flow loan

Amplia Therapeutics (ATX) has been granted a $2.1 million Research and Development (R&D) cash flow loan.
Vection Technologies (ASX:VR1) - Managing Director, Gianmarco Biagi

" Vection Technologies (ASX:VR1) beats first-half TCV goal with one month still to go

Virtual and artificial reality specialist Vection Technologies (VR1) has fallen in early trade despite surpassing its first-half contract value goal for the 2022...
Creso Pharma (ASX:CPH) - Creso Pharma

" Creso Pharma’s (ASX:CPH) Halucenex secures Dealer’s Licence amendment

Halucenex Life Sciences, a subsidiary of Creso Pharma (CPH), has secured an amendment to its Controlled Drugs and Substances Dealer’s Licence.

" Immutep (IMM) treats first five patients in solid tumour study

Immutep (IMM) has treated five patients in its study evaluating eftilagimod (efti) alpha in conjunction with standard of care chemotherapy.